iPSCs have great replicative ability and demonstrated potential to form functional cardiomyocytes (CMs). These CMs stand for a promising source for cell replacement therapy to treat heart disease, and they may act as a potent tool for drug discovery and disease modeling. Until now, a variety of approaches have been developed for producing iPSC-derived CMs and many are available in Creative Bioarray.

Creative Bioarray provides top quality service for directed-differentiation of iPSCs into cardiomyocytes using our proprietary induction protocol and reagents. We deliver ready-to-use, functional cardiomyocytes that are desirable in vitro models for high content toxicity and drug screening, and cell regeneration research. They are a feasible and physiologically relevant alternative to embryonic stem cell, primary cells, and animal models.

Workflow:

1. Recovery, Expansion and Validation of iPSCs/ESCs
2. Cardiomyocyte Differentiation
3. Characterization of differentiated cells by immunocytochemical (ICC) staining: 2 biomarkers (cTNT; SMA)

Deliverables:

1. Lineage-committed cardiomyocytes differentiated from iPSCs.

2. Report containing results and data:

• Phase contrast images of parental iPSC lines after expansion (milestone 1); and differentiated cardiomyocytes
• Videos of beating cardiomyocytes (before cryopreservation)
• Antibody staining images of cardiomyocytes using anti-TNT anti-SMA antibodies
• Freeze-thaw viability and mycoplasma testing